Top Page
Shanghai Junshi Biosciences Co., Ltd. Class H
(1877)
Shanghai Junshi Biosciences Co., Ltd. Class H (1877) vs. iShares MSCI Hong Kong ETF (EWH)
Shanghai Junshi Biosciences Co., Ltd. Class H Business Overview & Revenue Model
Shanghai Junshi Biosciences Co., Ltd. Class H Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.33B | 1.95B | 1.50B | 1.45B | 4.02B | 1.59B |
| Gross Profit | 1.89B | 1.54B | 835.26M | 927.21M | 2.77B | 1.22B |
| EBITDA | -769.18M | -935.50M | -2.16B | -2.52B | -476.32M | -1.58B |
| Net Income | -1.05B | -1.28B | -2.28B | -2.39B | -718.56M | -1.67B |
Balance Sheet | ||||||
| Total Assets | 11.68B | 10.80B | 11.36B | 12.58B | 11.05B | 8.01B |
| Cash, Cash Equivalents and Short-Term Investments | 3.51B | 2.93B | 3.78B | 6.00B | 3.50B | 3.39B |
| Total Debt | 3.49B | 2.93B | 1.79B | 1.32B | 628.20M | 850.78M |
| Total Liabilities | 5.28B | 4.85B | 4.02B | 2.78B | 2.72B | 2.17B |
| Stockholders Equity | 6.37B | 5.86B | 7.17B | 9.50B | 7.96B | 5.84B |
Cash Flow | ||||||
| Free Cash Flow | -1.51B | -2.12B | -2.85B | -2.17B | -1.53B | -2.09B |
| Operating Cash Flow | -897.88M | -1.43B | -2.01B | -1.78B | -641.90M | -1.50B |
| Investing Cash Flow | -497.16M | -892.78M | -892.42M | -467.62M | -1.88B | -697.98M |
| Financing Cash Flow | 1.67B | 1.02B | 681.04M | 4.64B | 2.67B | 4.41B |
Shanghai Junshi Biosciences Co., Ltd. Class H Technical Analysis
Shanghai Junshi Biosciences Co., Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | HK$34.13B | 38.35 | 27.37% | ― | 2.57% | 18.79% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$10.93B | 42.78 | 13.34% | ― | 206.58% | ― | |
45 Neutral | HK$24.44B | -16.84 | -161.12% | ― | -56.94% | -190.36% | |
43 Neutral | HK$39.44B | -25.46 | -15.06% | ― | 39.02% | 48.26% | |
41 Neutral | HK$23.00B | ― | -29.51% | ― | 32.07% | 33.55% | |
40 Underperform | HK$56.01B | -48.21 | -39.64% | ― | 46.14% | 39.56% |
Shanghai Junshi Biosciences Co., Ltd. Class H Corporate Events
Shanghai Junshi Biosciences Co., Ltd. announced that its wholly-owned subsidiary, Suzhou Union Biopharm Co., Ltd., has successfully passed an unannounced FDA on-site inspection for Current Good Manufacturing Practice (CGMP) compliance. This achievement marks the second successful FDA inspection for Suzhou Union, reinforcing the company’s high production standards and supporting its expansion strategy in the U.S. market. The successful inspection is expected to positively impact the company’s operations and strengthen its position in the global pharmaceutical industry.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$29.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. announced the convening of its 2025 third quarterly results briefing, scheduled for October 29, 2025. The briefing aims to provide investors with a comprehensive understanding of the company’s operating results and financial status for the third quarter of 2025, facilitating communication between the company and its stakeholders.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$29.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. announced that the U.S. FDA has approved its investigational new drug application for a phase II/III clinical study of JS207, a recombinant humanized anti-PD-1/VEGF bispecific antibody, for the neoadjuvant treatment of non-small cell lung cancer (NSCLC) patients. This approval marks a significant step for the company as it positions JS207 as a potential new treatment option for NSCLC, addressing unmet clinical needs and potentially improving patient outcomes in a highly prevalent and deadly cancer type.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$29.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. has announced that its board of directors will meet on October 28, 2025, to review and approve the company’s unaudited financial results for the nine months ending September 30, 2025. This meeting is significant as it will provide insights into the company’s financial health and performance, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$29.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. announced that its chairman, Mr. Xiong Jun, plans to increase his shareholding in the company by at least RMB100 million, with a minimum of RMB50 million allocated to A shares. As of October 2025, the shareholding increase plan has reached its midpoint, but due to various factors such as reporting windows and funding arrangements, the increase has not yet been completed. Mr. Xiong Jun intends to continue with the shareholding increase plan as opportunities arise, which may impact the company’s market position and shareholder confidence.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. announced adjustments to its 2025 A Share Option Incentive Scheme, reducing the number of participants from 251 to 235 and the total A Share Options from 26,175,871 to 25,965,871. These changes, approved by the Board of Directors and the Remuneration and Appraisal Committee, are not expected to materially impact the company’s financial condition or operations, and do not require further shareholder approval.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. announced the election of Dr. Yang Jin as an Independent Non-executive Director, effective September 29, 2025. This change also affects the composition of the Remuneration and Appraisal Committee and the Nomination Committee, with Dr. Yang Jin and Ms. Lu Kun taking new roles. The abolishment of the Board of Supervisors marks a significant shift in the company’s governance structure, potentially impacting its operational and strategic direction.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. announced the successful passing of all resolutions during its 2025 first extraordinary general meeting. The meeting saw significant participation from shareholders, with a notable percentage of shares represented. Key resolutions included the election of an Independent Non-executive Director and amendments to internal management policies, reflecting the company’s strategic focus on governance and operational efficiency.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. has announced a capital increase agreement involving its non-wholly owned subsidiary, JunTop Biosciences, and Shanghai Tanying Investment Partnership. This transaction, which is classified as a related party transaction under PRC laws, does not constitute a connected transaction under Hong Kong’s Listing Rules. The agreement signifies a strategic move to bolster financial resources, potentially enhancing the company’s market position and operational capabilities.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. has announced the composition of its board of directors and their roles within the company. This update includes the appointment of executive, non-executive, and independent non-executive directors, along with the establishment of five committees to oversee various aspects of the company’s governance and strategic direction.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. has announced the adjournment of its 2025 first extraordinary general meeting (EGM) to 29 September 2025. The meeting will address special resolutions regarding the proposed grant of H Share Options to Mr. Zhang Zhuobing and Dr. Yao Sheng, contingent upon the adoption of the 2025 H Share Option Incentive Scheme. This development is significant for stakeholders as it reflects the company’s ongoing efforts to incentivize key personnel, potentially impacting its strategic direction and market positioning.
The most recent analyst rating on (HK:1877) stock is a Sell with a HK$18.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. has announced the adjournment of its Extraordinary General Meeting (EGM) initially scheduled for September 26, 2025, now rescheduled to September 29, 2025. This postponement is to provide shareholders with additional time to consider special resolutions. The company has issued a supplemental proxy form and circular to guide shareholders on the new voting procedures, ensuring clarity and compliance in the decision-making process.
The most recent analyst rating on (HK:1877) stock is a Sell with a HK$18.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. announced a change in equity holdings, where the shareholders holding more than 5% of the company’s shares, including Shanghai Tanying Investment Partnership and its concerted parties, have reduced their total equity proportion from 8.96% to 7.91%. This change does not breach any commitments or trigger a mandatory tender offer obligation, indicating a strategic adjustment in shareholder structure without significant implications for the company’s operational commitments or market positioning.
The most recent analyst rating on (HK:1877) stock is a Sell with a HK$18.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. announced that its anti-IL-17A monoclonal antibody, JS005, has successfully met the primary and secondary endpoints in a Phase III clinical study for treating moderate to severe plaque psoriasis. This achievement marks a significant advancement in the company’s product pipeline, potentially enhancing its market position in the autoimmune disease treatment sector. The study demonstrated that JS005 significantly improved psoriasis symptoms compared to a placebo, with good safety results, and the company plans to submit a new drug application soon.
The most recent analyst rating on (HK:1877) stock is a Sell with a HK$18.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. has announced an extraordinary general meeting (EGM) scheduled for September 26, 2025, to discuss several key proposals. These include the election of an Independent Non-executive Director, amendments to internal management policies, changes in registered capital, and the abolishment of the Board of Supervisors. Additionally, the meeting will address the 2025 A and H Share Option Incentive Schemes, which aim to grant share options to directors and substantial shareholders, enhancing stakeholder engagement and potentially impacting the company’s strategic direction.
The most recent analyst rating on (HK:1877) stock is a Sell with a HK$18.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. has announced the proposed election of Dr. Yang Jin as an independent non-executive director, subject to shareholder approval at an upcoming extraordinary general meeting. This change follows the resignation of Dr. Yang Yue from the same position due to other work commitments. The company is also adjusting the composition of its Remuneration and Appraisal Committee and Nomination Committee. These changes are part of the company’s ongoing efforts to strengthen its board and governance structure.
The most recent analyst rating on (HK:1877) stock is a Sell with a HK$18.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. has announced the closure of its register of members of H shares from September 22 to September 26, 2025. This closure is to determine the entitlements of shareholders to attend and vote at the company’s first extraordinary general meeting on September 26, 2025, impacting shareholder participation and decision-making processes.
The most recent analyst rating on (HK:1877) stock is a Sell with a HK$18.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. has announced the proposed adoption of the 2025 H Share Option Incentive Scheme and the 2025 A Share Option Incentive Scheme, which are subject to shareholder approval. These schemes aim to attract, incentivize, and retain talent by aligning participants’ interests with those of the company and its shareholders. The proposed grants include 13,210,000 H Share Options to several executive directors and 8,000,000 A Share Options to a substantial shareholder, Mr. Xiong. The adoption of these schemes is expected to contribute to the company’s long-term growth and enhance shareholder value.
The most recent analyst rating on (HK:1877) stock is a Sell with a HK$18.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. announced that its subsidiary, Shanghai JunTop Biosciences Co., Ltd., has received approval from the National Medical Products Administration to conduct clinical trials for its JT118 injection. This investigational new drug is a recombinant protein vaccine aimed at preventing monkeypox virus infection, marking a significant step as no such vaccine is currently approved in China. The vaccine has shown promising results in preclinical studies, demonstrating significant protection and a favorable safety profile. This development could enhance the company’s position in the pharmaceutical industry, particularly in the field of infectious disease prevention.
The most recent analyst rating on (HK:1877) stock is a Sell with a HK$18.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. announced the convening of its 2025 interim results briefing to be held on September 8, 2025. The briefing aims to provide investors with a comprehensive understanding of the company’s operating results and financial status for the first half of 2025. The event will be conducted online via the Shanghai Stock Exchange Roadshow Center, allowing investors to interact and ask questions. This initiative reflects the company’s commitment to transparency and investor engagement, potentially impacting its market perception and stakeholder relations positively.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$29.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. reported a significant increase in revenue and a reduction in losses for the first half of 2025, driven by strong domestic sales of its core product, TUOYI. The company also achieved notable progress in its R&D efforts, expanding its innovative pipeline and securing regulatory approvals for key products, which positions it well for future growth and international development.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$29.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. has outlined the terms of reference for its Remuneration and Appraisal Committee of the Board of Directors. This document details the committee’s composition, duties of the chairman, work procedures, and rules of procedure, which are crucial for ensuring effective governance and oversight within the company.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$29.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. has released the terms of reference for the Nomination Committee of its Board of Directors. This document outlines the general provisions, composition, terms of reference, duties of the chairman, work procedures, rules of procedure, and supplementary provisions for the committee. The release of these terms is a significant step in ensuring structured governance and effective oversight within the company, which may enhance its operational efficiency and strategic decision-making processes.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$29.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. has outlined the terms of reference for its Strategic Committee of the Board of Directors. This announcement details the committee’s composition, duties of the chairman, and procedural rules, which are crucial for guiding the company’s strategic direction and governance.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$29.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. has released the terms of reference for its Compliance Committee of the Board of Directors. This document outlines the general provisions, composition, terms of reference, rules of procedure, and supplementary provisions for the committee, which plays a crucial role in ensuring the company’s adherence to regulatory and ethical standards. The establishment of these guidelines is expected to enhance the company’s governance framework and reinforce its commitment to compliance, potentially impacting its operational integrity and stakeholder trust.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$29.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. has announced several significant changes, including an increase in registered capital following a successful placement of new H shares, which raises their total issued share capital. Additionally, the company plans to abolish its Board of Supervisors, with its powers being transferred to the Audit Committee, in response to updates in Chinese corporate law. The company also proposes amendments to its Articles of Association and internal policies to align with the latest legal requirements and improve operational efficiency. These changes are expected to streamline governance and enhance compliance with regulatory standards, potentially impacting the company’s market positioning and stakeholder relations.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$29.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. has released the terms of reference for its Audit Committee of the Board of Directors. This document outlines the general provisions, composition, duties and powers, chairman’s responsibilities, working procedure, rules of procedure, and supplementary provisions for the committee. The release of these terms is a significant step in enhancing the company’s corporate governance and ensuring transparency and accountability in its financial reporting processes.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$29.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. has released a special report detailing the deposit and actual use of proceeds for the first half of 2025. The report, in compliance with regulatory guidelines, outlines the company’s financial activities following its initial public offering of A shares in 2020, highlighting its adherence to regulatory standards and transparency in financial operations.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$29.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. announced a plan for the reduction of shareholding by Shanghai Tanying Investment Partnership, a substantial shareholder holding more than 5% of the company’s shares. The reduction will involve no more than 20,533,797 shares, accounting for up to 2% of the total share capital, through block trading. This move is driven by the maturity of the fund and liquidity arrangements, and it reflects Shanghai Tanying’s long-term optimism about the company’s development.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. has announced that its board of directors will convene on August 26, 2025, to review and approve the company’s interim financial results for the first half of the year ending June 30, 2025. This meeting is significant as it will provide insights into the company’s financial health and operational performance, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. announced the acceptance of a supplemental new drug application for toripalimab, in combination with disitamab vedotin, as a first-line treatment for HER2-expressing urothelial carcinoma. This development is based on successful phase III clinical trial results, which demonstrated significant improvements in progression-free and overall survival for patients compared to traditional chemotherapy. The acceptance of this application highlights the company’s ongoing efforts to expand its treatment options and strengthen its position in the oncology market, addressing unmet clinical needs in the treatment of advanced urothelial carcinoma.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.